Sunitinib malate is a small molecule, multi-targeted receptor tyrosine kinase inhibitor. It potently inhibits signaling through PDGFR, VEGFR, KIT, and FLT3. Through these effects, sunitinib malate inhibits both tumor cell growth and angiogenesis, leading to reduced tumor vascularization and cancer cell death. It has been approved by the FDA for the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.
